Phase Ib allergen challenge trial of R 343 in patients with mild allergic asthma.

Trial Profile

Phase Ib allergen challenge trial of R 343 in patients with mild allergic asthma.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2012

At a glance

  • Drugs R 343 (Primary) ; Fluticasone propionate
  • Indications Allergic asthma
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
    • 05 Aug 2011 Results will be presented at an analyst/investor meeting in New York City in October 2011
    • 05 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top